Core Insights - Regentis Biomaterials Ltd. is expanding its U.S. clinical site network to enhance its infrastructure for ongoing and future clinical programs [1] - The company has surpassed 50% patient enrollment in its pivotal Phase III study of GelrinC® for knee cartilage repair [1] - GelrinC is positioned to transform the cartilage repair market with its off-the-shelf regenerative products [1] Company Developments - The expansion of clinical sites is expected to accelerate patient enrollment in the ongoing Phase III study [1] - The new sites will also support future clinical programs beyond the current study [1] Industry Impact - GelrinC is anticipated to significantly impact the cartilage repair market by providing innovative regenerative solutions [1]
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.